ClinicalTrials.gg
CompletedNCT00472199Updated Jun 27, 2014Results posted

Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)

A Phase 4 interventional study of Pramipexole and Placebo in Restless Legs Syndrome, sponsored by Boehringer Ingelheim. Completed at 42 sites in 9 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2014-06-27.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
331
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing pramipexole in Restless Legs Syndrome — none open to participants now, 1 under way, none of them phase 3. Pramipexole · Restless Legs Syndrome.

Enrollment
6th of 17
331 · median 154
Started
2007
the only one that year
Phase 4
8 of 17
none open now
Registered
12th of 17
by date
Lead sponsor
12 of 17
Boehringer Ingelheim

Among the 17 studies testing pramipexole in Restless Legs Syndrome, this one is the 6th largest by enrollment, is the only one that started in 2007, is one of 8 in phase 4, and was the 12th registered.

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Open to participants now

None of the 17 studies testing pramipexole in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →

About pramipexole

Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing pramipexole in Restless Legs Syndrome as a file.
02

Study summary

The primary objective of the current study will be the evaluation of long-term efficacy of a 26-weeks treatment with pramipexole in patients with idiopathic moderate to severe Restless Legs Syndrome (RLS) in comparison to placebo.

The key secondary objectives are to assess the effects on clinical global impressions - global improvement (CGI-I) (based on CGI-I responder rate) and on RLS (based on IRLS responder rate) for 26 weeks under pramipexole in comparison to placebo. Further secondary objectives are to investigate the incidence and severity of augmentation and rebound and to assess the effects on patient global impression (PGI) (based on PGI responder rate), on RLS symptoms (based on the RLS-6 scales), on associated mood disturbance (based on item 10 of the IRLS), on pain in limbs (based on a visual analogue scale (VAS)), on quality of life in RLS (based on Johns Hopkins RLS-QoL), on general quality of life Short Form 36 (SF-36) and on safety (based on adverse events (AE) profile) of pramipexole in comparison to placebo.

03

Conditions studied

  • Restless Legs Syndrome
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written consistent with International Conference on Harmonization - Good Clinical Practice (ICH-GCP) and local Institutional Review Board/Independent Ethics Committee (IRB/IEC) requirements obtained prior to any study procedures being performed and the ability and willingness to comply with study treatment regimen and to attend study assessments
  2. Male or female out-patients aged 18-85 years
  3. Diagnosis of idiopathic RLS according to the clinical RLS criteria of the International Restless Legs Syndrome Study Group (IRLSSG) [P03-03355]. All four criteria must be present to fulfil the diagnosis of RLS.
  4. RLS symptoms present at least 2 to 3 days per week during the last 3 months prior to baseline (Visit 2)
  5. IRLS total score >15 at baseline (Visit 2)

Exclusion criteria

Exclusion Criteria:

  1. Women of (i.e. premenopausal women, or women less than 6 months after last menses) who do not use during the clinical trial an adequate method of such as: double barrier protection (e.g. diaphragm or condom and spermicide), intrauterine device, hormonal therapy (oral, injectable, or subcutaneous), or partner's surgical sterilization
  2. Any woman of child-bearing potential not having a negative pregnancy test at screening
  3. Breastfeeding women
  4. Patients with known to pramipexole or any other component of the product or placebo tablets
  5. Diagnosis of augmentation under previous pharmacological RLS treatment
  6. Concomitant or previous pharmacologic therapy as follows: Any intake of dopamine agonists within 14 days prior to baseline (Visit 2); Any intake of levodopa within 14 days prior to baseline (Visit 2); Unsuccessful prior treatment with non-ergot dopamine agonists (e.g. pramipexole, ropinirole);
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
331 participants (actual)

Study arms

  • Experimental
    Pramipexole

    4 weeks of flexible dose-titration (to optimise efficacy and tolerability), starting at 0.125 mg once daily with the potential to increase or decrease the dose in steps to 0.25 mg, 0.5 mg and 0.75 mg, with the final dose level subsequently fixed for 22 weeks.

    Drug: Pramipexole

  • Placebo comparator
    Placebo

    4 weeks of flexible dose-titration as for the investigational product; with the dose subsequently fixed for 22 weeks.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in International Restless Legs Syndrome Study Group Rating Scale (IRLS) Total Score After 26 Weeks

    IRLS total score ranging from 0 (no RLS symptoms) to 40 (very severe RLS symptoms)

    Time frame: Baseline and 26 weeks

Secondary outcomes

  1. Clinical Global Impression - Global Improvement (CGI-I) Responder Rate

    CGI-I scores ranging from '1' (very much improved) to '7' (very much worse), CGI-I responder have scoring 1 or 2 (at least much improved)

    Time frame: after 26 weeks of treatment

  2. International Restless Legs Syndrome (IRLS) Study Group Rating Scale Responder Rate

    IRLS response was defined as at least 50% reduction in IRLS total score from baseline. IRLS total score ranging from 0 (no RLS symptoms) to 40 (very severe symptoms)

    Time frame: after 26 weeks of treatment

  3. Patient Global Impression (PGI) Responder Rate

    PGI scores ranging from '1' (very much better) to '7' (very much worse), PGI responder have scoring 1 or 2 (at least much better)

    Time frame: after 26 weeks of treatment

  4. Change From Baseline in Restless Legs Syndrome-6 (RLS-6) Score "Satisfaction With Sleep" After 26 Weeks

    The score is an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week

    Time frame: baseline and 26 weeks of treatment

  5. Change From Baseline in RLS-6 Score "Severity Falling Asleep" After 26 Weeks

    The score is an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week

    Time frame: Baseline and 26 weeks of treatment

  6. Change From Baseline in RLS-6 Score "Severity During the Night" After 26 Weeks

    The question was rated on an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week

    Time frame: baseline and 26 weeks of treatment

  7. Change From Baseline in RLS-6 Score "Severity During the Day When at Rest" After 26 Weeks

    The score is an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week

    Time frame: Baseline and 26 weeks of treatment

  8. Change From Baseline RLS-6 Score "Severity During the Day Engaged in Activities" After 26 Weeks

    The score is an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week

    Time frame: Baseline and 26 weeks of treatment

  9. Change From Baseline in RLS-6 Score "Tired or Sleepy During the Day" After 26 Weeks

    The score is an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week

    Time frame: Baseline and 26 weeks of treatment

  10. Change From Baseline in IRLS Mood Disturbance Score (Item 10) After 26 Weeks

    Mood disturbance associated with RLS symptoms ranging from 0 (none) to 4 (very severe)

    Time frame: Baseline and 26 weeks of treatment

  11. Change From Baseline in Visual Analogue Scale (VAS) Score for Pain in Limbs After 26 Weeks

    The scale measures pain on a continuous 100 mm axis ranging from no pain (0 mm) to unbearable pain (100 mm)

    Time frame: Baseline and 26 weeks of treatment

  12. Change From Baseline in Quality of Life in RLS (RLS QoL) Score After 26 Weeks

    RLS QoL total score ranging from 0 to 100 with higher values indicating better quality of life

    Time frame: Baseline and 26 weeks of treatment

  13. Change From Baseline in Short Form-36 (SF-36) Dimension Bodily Pain After 26 Weeks

    Score ranging from 0 to 100 with higher scores indicating less bodily pain

    Time frame: Baseline and 26 weeks

  14. Change From Baseline in SF-36 Dimension General Health After 26 Weeks

    Score ranging from 0 to 100 with higher scores indicating better health status

    Time frame: Baseline and 26 weeks

  15. Change From Baseline in SF-36 Dimension Mental Health After 26 Weeks

    Score ranging from 0 to 100 with higher scores indicating better mental health

    Time frame: Baseline and 26 weeks

  16. Change From Baseline in SF-36 Dimension Physical Functioning After 26 Weeks

    Score ranging from 0 to 100 with higher scores indicating better physical functioning

    Time frame: Baseline and 26 weeks

  17. Change From Baseline in SF-36 Dimension Role Limitations Due to Emotional Problems After 26 Weeks

    Score ranging from 0 to 100 with higher scores indicating less limitations due to emotional problems

    Time frame: Baseline and 26 weeks

  18. Change From Baseline in SF-36 Dimension Role Limitations Due to Physical Problems After 26 Weeks

    Score ranging from 0 to 100 with higher scores indicating less limitations due to physical problems

    Time frame: Baseline and 26 weeks

  19. Change From Baseline in SF-36 Dimension Social Functioning After 26 Weeks

    Score ranging from 0 to 100 with higher scores indicating better social functioning

    Time frame: Baseline and 26 weeks

  20. Change From Baseline in SF-36 Dimension Vitality After 26 Weeks

    Score ranging from 0 to 100 with higher scores indicating better vitality

    Time frame: Baseline and 26 weeks

  21. Change From Baseline in SF-36 Dimension Mental Component Summary After 26 Weeks

    Score ranging from 0 to 100 with higher scores indicating better health

    Time frame: Baseline and 26 weeks

  22. Change From Baseline in SF-36 Dimension Physical Component Summary After 26 Weeks

    Score ranging from 0 to 100 with higher scores indicating better health

    Time frame: Baseline and 26 weeks

  23. Diagnosis of Classified Augmentation According to Independent Expert Panel

    Augmentation is a worsening of RLS symptoms and may manifest as increased severity and the involvement of other extremities or as a shift of RLS symptoms to a time period that is 2 or more hours earlier than was typical of the time of symptom onset during the initial course of beneficial stable treatment or the state before recently starting treatment.

    Time frame: after at least 4 weeks of treatment

  24. Worsening of RLS Symptoms (by at Least 4 Points in the IRLS Total Score Compared to Baseline) After Treatment Discontinuation

    Worsening of RLS symptoms, in comparison to baseline, following abrupt treatment discontinuation (for patients with no added RLS therapy after study drug discontinuation). Assessment of worsening of RLS was based on the IRLS total score assessed 7 ± 1 days after treatment discontinuation (the end of the study or premature discontinuation) compared with that at baseline. Analysis considered the number of patients experiencing a clinically relevant deterioration of ≥4 points in total IRLS score 7 ± 1 days after discontinuation of trial medication compared with baseline.

    Time frame: after at least 1 week of treatment discontinuation

  25. Baseline, Week 26 Mean Supine Systolic Blood Pressure

    Time frame: Baseline, Week 26

  26. Baseline, Week 26 Mean Standing Systolic Blood Pressure

    Time frame: Baseline, Week 26

  27. Baseline, Week 26 Mean Supine Diastolic Blood Pressure

    Time frame: Baseline, Week 26

  28. Baseline, Week 26 Mean Standing Diastolic Blood Pressure

    Time frame: Baseline, Week 26

  29. Baseline, Week 26 Mean Supine Pulse Rate

    Time frame: Baseline, Week 26

  30. Baseline, Week 26 Mean Standing Pulse Rate

    Time frame: Baseline, Week 26

07

Results

Posted Nov 17, 2009

Participant flow

Participant flow — Overall Study
MilestonePramipexolePlacebo
Started166163
Completed131103
Not completed3560
Withdrew: Adverse event1923
Withdrew: Lack of efficacy425
Withdrew: Lost to follow-up24
Withdrew: Protocol violation32
Withdrew: Withdrawal by subject65
Withdrew: Personal reason01
Withdrew: Patient was asymptomatic10

Outcome measures

PrimaryChange From Baseline in International Restless Legs Syndrome Study Group Rating Scale (IRLS) Total Score After 26 Weeks

IRLS total score ranging from 0 (no RLS symptoms) to 40 (very severe RLS symptoms)

Time frame:
Baseline and 26 weeks
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in International Restless Legs Syndrome Study Group Rating Scale (IRLS) Total Score After 26 Weeks
Scores on a scalePramipexolePlacebo
Change From Baseline in International Restless Legs Syndrome Study Group Rating Scale (IRLS) Total Score After 26 Weeks-13.7 ± 0.8-11.1 ± 0.8
Statistical analysis
  • Pramipexole vs Placebo · ANCOVA · p = 0.0077 · Mean difference (net): -2.6 · 95% CI -4.6 to -0.7
SecondaryClinical Global Impression - Global Improvement (CGI-I) Responder Rate

CGI-I scores ranging from '1' (very much improved) to '7' (very much worse), CGI-I responder have scoring 1 or 2 (at least much improved)

Time frame:
after 26 weeks of treatment
Reported as:
Number · participants
Clinical Global Impression - Global Improvement (CGI-I) Responder Rate
participantsPramipexolePlacebo
CGI-I responder (at least much improved)11180
CGI-I non-responder5179
Statistical analysis
  • Pramipexole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0010
SecondaryInternational Restless Legs Syndrome (IRLS) Study Group Rating Scale Responder Rate

IRLS response was defined as at least 50% reduction in IRLS total score from baseline. IRLS total score ranging from 0 (no RLS symptoms) to 40 (very severe symptoms)

Time frame:
after 26 weeks of treatment
Reported as:
Number · participants
International Restless Legs Syndrome (IRLS) Study Group Rating Scale Responder Rate
participantsPramipexolePlacebo
IRLS responder9568
IRLS non-responder6791
Statistical analysis
  • Pramipexole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0044
SecondaryPatient Global Impression (PGI) Responder Rate

PGI scores ranging from '1' (very much better) to '7' (very much worse), PGI responder have scoring 1 or 2 (at least much better)

Time frame:
after 26 weeks of treatment
Reported as:
Number · participants
Patient Global Impression (PGI) Responder Rate
participantsPramipexolePlacebo
PGI responder (much better or very much better)10170
PGI non-responder6189
Statistical analysis
  • Pramipexole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0011
SecondaryChange From Baseline in Restless Legs Syndrome-6 (RLS-6) Score "Satisfaction With Sleep" After 26 Weeks

The score is an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week

Time frame:
baseline and 26 weeks of treatment
Reported as:
Median · Scores on a scale
Change From Baseline in Restless Legs Syndrome-6 (RLS-6) Score "Satisfaction With Sleep" After 26 Weeks
Scores on a scalePramipexolePlacebo
Change From Baseline in Restless Legs Syndrome-6 (RLS-6) Score "Satisfaction With Sleep" After 26 Weeks-2.5 (-5.0 to 0.0)-2 (-4.0 to 0.0)
Statistical analysis
  • Pramipexole vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0489 · Median difference (final values): -1.0 · 95% CI -1.1 to -0.9
SecondaryChange From Baseline in RLS-6 Score "Severity Falling Asleep" After 26 Weeks

The score is an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week

Time frame:
Baseline and 26 weeks of treatment
Reported as:
Median · Scores on a scale
Change From Baseline in RLS-6 Score "Severity Falling Asleep" After 26 Weeks
Scores on a scalePramipexolePlacebo
Change From Baseline in RLS-6 Score "Severity Falling Asleep" After 26 Weeks-3 (-5.0 to 0.0)-1 (-4 to 0.0)
Statistical analysis
  • Pramipexole vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0315 · Median difference (final values): 0.0 · 95% CI -0.0 to 0.0
SecondaryChange From Baseline in RLS-6 Score "Severity During the Night" After 26 Weeks

The question was rated on an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week

Time frame:
baseline and 26 weeks of treatment
Reported as:
Median · Scores on a scale
Change From Baseline in RLS-6 Score "Severity During the Night" After 26 Weeks
Scores on a scalePramipexolePlacebo
Change From Baseline in RLS-6 Score "Severity During the Night" After 26 Weeks-3 (-5.0 to 0.0)-2 (-5.0 to 0.0)
Statistical analysis
  • Pramipexole vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0735 · Median difference (final values): 0.0 · 95% CI -0.0 to 0.0
SecondaryChange From Baseline in RLS-6 Score "Severity During the Day When at Rest" After 26 Weeks

The score is an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week

Time frame:
Baseline and 26 weeks of treatment
Reported as:
Median · Scores on a scale
Change From Baseline in RLS-6 Score "Severity During the Day When at Rest" After 26 Weeks
Scores on a scalePramipexolePlacebo
Change From Baseline in RLS-6 Score "Severity During the Day When at Rest" After 26 Weeks-3 (-5.0 to 0.0)-1 (-4.0 to 0.0)
Statistical analysis
  • Pramipexole vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.8410 · Median difference (final values): 0.0 · 95% CI -0.0 to 0.0
SecondaryChange From Baseline RLS-6 Score "Severity During the Day Engaged in Activities" After 26 Weeks

The score is an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week

Time frame:
Baseline and 26 weeks of treatment
Reported as:
Median · Scores on a scale
Change From Baseline RLS-6 Score "Severity During the Day Engaged in Activities" After 26 Weeks
Scores on a scalePramipexolePlacebo
Change From Baseline RLS-6 Score "Severity During the Day Engaged in Activities" After 26 Weeks0 (-1.0 to 0.0)0 (-1.0 to 0.0)
Statistical analysis
  • Pramipexole vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.9241 · Median difference (final values): 0.0 · 95% CI -0.0 to 0.0
SecondaryChange From Baseline in RLS-6 Score "Tired or Sleepy During the Day" After 26 Weeks

The score is an 11-point Likert scale, ranging from "none/not at all" (0) to "very severe" (10), to reflect the patient's condition during the previous week

Time frame:
Baseline and 26 weeks of treatment
Reported as:
Median · Scores on a scale
Change From Baseline in RLS-6 Score "Tired or Sleepy During the Day" After 26 Weeks
Scores on a scalePramipexolePlacebo
Change From Baseline in RLS-6 Score "Tired or Sleepy During the Day" After 26 Weeks-1 (-3.0 to 0.0)-1 (-3.0 to 0.0)
Statistical analysis
  • Pramipexole vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.8093 · Median difference (final values): 0.0 · 95% CI -0.0 to 0.0
SecondaryChange From Baseline in IRLS Mood Disturbance Score (Item 10) After 26 Weeks

Mood disturbance associated with RLS symptoms ranging from 0 (none) to 4 (very severe)

Time frame:
Baseline and 26 weeks of treatment
Reported as:
Median · scores on a scale
Change From Baseline in IRLS Mood Disturbance Score (Item 10) After 26 Weeks
scores on a scalePramipexolePlacebo
Change From Baseline in IRLS Mood Disturbance Score (Item 10) After 26 Weeks-1 (-2.0 to 0.0)-1 (-2.0 to 0.0)
Statistical analysis
  • Pramipexole vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0583 · Median difference (final values): 0.0 · 95% CI -0.0 to 0.0
SecondaryChange From Baseline in Visual Analogue Scale (VAS) Score for Pain in Limbs After 26 Weeks

The scale measures pain on a continuous 100 mm axis ranging from no pain (0 mm) to unbearable pain (100 mm)

Time frame:
Baseline and 26 weeks of treatment
Reported as:
Median · Scores on a scale
Change From Baseline in Visual Analogue Scale (VAS) Score for Pain in Limbs After 26 Weeks
Scores on a scalePramipexolePlacebo
Change From Baseline in Visual Analogue Scale (VAS) Score for Pain in Limbs After 26 Weeks-26 (-47.0 to -5.0)-15 (-46.0 to 0.0)
Statistical analysis
  • Pramipexole vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0916 · Median difference (final values): -5.0 · 95% CI -5.5 to -4.5
SecondaryChange From Baseline in Quality of Life in RLS (RLS QoL) Score After 26 Weeks

RLS QoL total score ranging from 0 to 100 with higher values indicating better quality of life

Time frame:
Baseline and 26 weeks of treatment
Reported as:
Median · Scores on a scale
Change From Baseline in Quality of Life in RLS (RLS QoL) Score After 26 Weeks
Scores on a scalePramipexolePlacebo
Change From Baseline in Quality of Life in RLS (RLS QoL) Score After 26 Weeks15 (5.0 to 25.0)12.5 (2.5 to 27.5)
Statistical analysis
  • Pramipexole vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.5905 · Median difference (final values): 2.5 · 95% CI 2.2 to 2.8
SecondaryChange From Baseline in Short Form-36 (SF-36) Dimension Bodily Pain After 26 Weeks

Score ranging from 0 to 100 with higher scores indicating less bodily pain

Time frame:
Baseline and 26 weeks
Reported as:
Median · Scores on a scale
Change From Baseline in Short Form-36 (SF-36) Dimension Bodily Pain After 26 Weeks
Scores on a scalePramipexolePlacebo
Change From Baseline in Short Form-36 (SF-36) Dimension Bodily Pain After 26 Weeks12 (0.0 to 31.0)9 (-1.0 to 24.5)
Statistical analysis
  • Pramipexole vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0179 · Median difference (final values): 2.0 · 95% CI 1.6 to 2.4
SecondaryChange From Baseline in SF-36 Dimension General Health After 26 Weeks

Score ranging from 0 to 100 with higher scores indicating better health status

Time frame:
Baseline and 26 weeks
Reported as:
Median · Scores on a scale
Change From Baseline in SF-36 Dimension General Health After 26 Weeks
Scores on a scalePramipexolePlacebo
Change From Baseline in SF-36 Dimension General Health After 26 Weeks0 (-5.0 to 10.0)0 (-5.0 to 10.0)
Statistical analysis
  • Pramipexole vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.5450 · Median difference (final values): 2.0 · 95% CI 1.7 to 2.3
SecondaryChange From Baseline in SF-36 Dimension Mental Health After 26 Weeks

Score ranging from 0 to 100 with higher scores indicating better mental health

Time frame:
Baseline and 26 weeks
Reported as:
Median · Scores on a scale
Change From Baseline in SF-36 Dimension Mental Health After 26 Weeks
Scores on a scalePramipexolePlacebo
Change From Baseline in SF-36 Dimension Mental Health After 26 Weeks5 (-5.0 to 15.0)5 (-5.0 to 10.0)
Statistical analysis
  • Pramipexole vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.1456 · Median difference (final values): 0.0 · 95% CI -0.3 to 0.3
SecondaryChange From Baseline in SF-36 Dimension Physical Functioning After 26 Weeks

Score ranging from 0 to 100 with higher scores indicating better physical functioning

Time frame:
Baseline and 26 weeks
Reported as:
Median · Scores on a scale
Change From Baseline in SF-36 Dimension Physical Functioning After 26 Weeks
Scores on a scalePramipexolePlacebo
Change From Baseline in SF-36 Dimension Physical Functioning After 26 Weeks0 (0.0 to 10.0)0 (-5.0 to 10.0)
Statistical analysis
  • Pramipexole vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.2915 · Median difference (final values): 0.0 · 95% CI -0.4 to 0.4
SecondaryChange From Baseline in SF-36 Dimension Role Limitations Due to Emotional Problems After 26 Weeks

Score ranging from 0 to 100 with higher scores indicating less limitations due to emotional problems

Time frame:
Baseline and 26 weeks
Reported as:
Median · Scores on a scale
Change From Baseline in SF-36 Dimension Role Limitations Due to Emotional Problems After 26 Weeks
Scores on a scalePramipexolePlacebo
Change From Baseline in SF-36 Dimension Role Limitations Due to Emotional Problems After 26 Weeks0 (-8.3 to 16.7)0 (0.0 to 16.7)
Statistical analysis
  • Pramipexole vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.3131 · Median difference (final values): 0.0 · 95% CI -0.4 to 0.4
SecondaryChange From Baseline in SF-36 Dimension Role Limitations Due to Physical Problems After 26 Weeks

Score ranging from 0 to 100 with higher scores indicating less limitations due to physical problems

Time frame:
Baseline and 26 weeks
Reported as:
Median · Scores on a scale
Change From Baseline in SF-36 Dimension Role Limitations Due to Physical Problems After 26 Weeks
Scores on a scalePramipexolePlacebo
Change From Baseline in SF-36 Dimension Role Limitations Due to Physical Problems After 26 Weeks6.3 (0.0 to 18.8)6.3 (0.0 to 18.8)
Statistical analysis
  • Pramipexole vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.5713 · Median difference (final values): 0.0 · 95% CI -0.4 to 0.4
SecondaryChange From Baseline in SF-36 Dimension Social Functioning After 26 Weeks

Score ranging from 0 to 100 with higher scores indicating better social functioning

Time frame:
Baseline and 26 weeks
Reported as:
Median · Scores on a scale
Change From Baseline in SF-36 Dimension Social Functioning After 26 Weeks
Scores on a scalePramipexolePlacebo
Change From Baseline in SF-36 Dimension Social Functioning After 26 Weeks0 (0.0 to 12.5)0 (0.0 to 25.0)
Statistical analysis
  • Pramipexole vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.8432 · Median difference (final values): 0.0 · 95% CI -0.4 to 0.4
SecondaryChange From Baseline in SF-36 Dimension Vitality After 26 Weeks

Score ranging from 0 to 100 with higher scores indicating better vitality

Time frame:
Baseline and 26 weeks
Reported as:
Median · Scores on a scale
Change From Baseline in SF-36 Dimension Vitality After 26 Weeks
Scores on a scalePramipexolePlacebo
Change From Baseline in SF-36 Dimension Vitality After 26 Weeks6.3 (0.0 to 18.8)3.1 (-6.3 to 12.5)
Statistical analysis
  • Pramipexole vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.0206 · Median difference (final values): 6.3 · 95% CI 5.9 to 6.6
SecondaryChange From Baseline in SF-36 Dimension Mental Component Summary After 26 Weeks

Score ranging from 0 to 100 with higher scores indicating better health

Time frame:
Baseline and 26 weeks
Reported as:
Median · Scores on a scale
Change From Baseline in SF-36 Dimension Mental Component Summary After 26 Weeks
Scores on a scalePramipexolePlacebo
Change From Baseline in SF-36 Dimension Mental Component Summary After 26 Weeks1.7 (-2.4 to 8.3)1.9 (-2.3 to 6.7)
Statistical analysis
  • Pramipexole vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.5602 · Median difference (final values): 0.6 · 95% CI 0.4 to 0.8
SecondaryChange From Baseline in SF-36 Dimension Physical Component Summary After 26 Weeks

Score ranging from 0 to 100 with higher scores indicating better health

Time frame:
Baseline and 26 weeks
Reported as:
Median · Scores on a scale
Change From Baseline in SF-36 Dimension Physical Component Summary After 26 Weeks
Scores on a scalePramipexolePlacebo
Change From Baseline in SF-36 Dimension Physical Component Summary After 26 Weeks2.1 (-0.5 to 7.5)2 (-2.0 to 5.9)
Statistical analysis
  • Pramipexole vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.1360 · Median difference (final values): 1.0 · 95% CI 0.8 to 1.1
SecondaryDiagnosis of Classified Augmentation According to Independent Expert Panel

Augmentation is a worsening of RLS symptoms and may manifest as increased severity and the involvement of other extremities or as a shift of RLS symptoms to a time period that is 2 or more hours earlier than was typical of the time of symptom onset during the initial course of beneficial stable treatment or the state before recently starting treatment.

Time frame:
after at least 4 weeks of treatment
Reported as:
Number · participants
Diagnosis of Classified Augmentation According to Independent Expert Panel
participantsPramipexolePlacebo
Diagnosis of Classified Augmentation According to Independent Expert Panel1814
SecondaryWorsening of RLS Symptoms (by at Least 4 Points in the IRLS Total Score Compared to Baseline) After Treatment Discontinuation

Worsening of RLS symptoms, in comparison to baseline, following abrupt treatment discontinuation (for patients with no added RLS therapy after study drug discontinuation). Assessment of worsening of RLS was based on the IRLS total score assessed 7 ± 1 days after treatment discontinuation (the end of the study or premature discontinuation) compared with that at baseline. Analysis considered the number of patients experiencing a clinically relevant deterioration of ≥4 points in total IRLS score 7 ± 1 days after discontinuation of trial medication compared with baseline.

Time frame:
after at least 1 week of treatment discontinuation
Reported as:
Number · participants
Worsening of RLS Symptoms (by at Least 4 Points in the IRLS Total Score Compared to Baseline) After Treatment Discontinuation
participantsPramipexolePlacebo
Worsening of RLS Symptoms (by at Least 4 Points in the IRLS Total Score Compared to Baseline) After Treatment Discontinuation142
Statistical analysis
  • Pramipexole vs Placebo · Mantel Haenszel · p = 0.0022
SecondaryBaseline, Week 26 Mean Supine Systolic Blood Pressure
Time frame:
Baseline, Week 26
Reported as:
Mean · mm Hg
Baseline, Week 26 Mean Supine Systolic Blood Pressure
mm HgPramipexolePlacebo
Baseline133.4 ± 16.9132.7 ± 18.4
Week 26132.3 ± 16.4132.2 ± 16.5
SecondaryBaseline, Week 26 Mean Standing Systolic Blood Pressure
Time frame:
Baseline, Week 26
Reported as:
Mean · mm Hg
Baseline, Week 26 Mean Standing Systolic Blood Pressure
mm HgPramipexolePlacebo
Baseline132.6 ± 17.3130.6 ± 18.2
Week 26132.4 ± 18.2130.1 ± 17.1
SecondaryBaseline, Week 26 Mean Supine Diastolic Blood Pressure
Time frame:
Baseline, Week 26
Reported as:
Mean · mm Hg
Baseline, Week 26 Mean Supine Diastolic Blood Pressure
mm HgPramipexolePlacebo
Baseline79.2 ± 9.779.6 ± 9.7
Week 2678.3 ± 9.779.5 ± 9.4
SecondaryBaseline, Week 26 Mean Standing Diastolic Blood Pressure
Time frame:
Baseline, Week 26
Reported as:
Mean · mm Hg
Baseline, Week 26 Mean Standing Diastolic Blood Pressure
mm HgPramipexolePlacebo
Baseline82.7 ± 10.581.7 ± 10.7
Week 2680.5 ± 10.680.8 ± 10.0
SecondaryBaseline, Week 26 Mean Supine Pulse Rate
Time frame:
Baseline, Week 26
Reported as:
Mean · bpm
Baseline, Week 26 Mean Supine Pulse Rate
bpmPramipexolePlacebo
Baseline68.5 ± 9.668.7 ± 10.6
Week 2669.1 ± 8.968.3 ± 10.6
SecondaryBaseline, Week 26 Mean Standing Pulse Rate
Time frame:
Baseline, Week 26
Reported as:
Mean · bpm
Baseline, Week 26 Mean Standing Pulse Rate
bpmPramipexolePlacebo
Baseline74.6 ± 10.274.0 ± 10.7
Week 2674.1 ± 8.975.0 ± 10.6

Adverse events

Collected over 26 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pramipexole—8/166 (4.8%)70/166 (42.2%)
Placebo—3/163 (1.8%)58/163 (35.6%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventPramipexolePlacebo
AppendicitisInfections and infestations0/1661/163
Viral infectionInfections and infestations0/1661/163
Orthostatic hypotensionVascular disorders0/1661/163
Crohn's diseaseGastrointestinal disorders0/1661/163
VomitingGastrointestinal disorders0/1661/163
Urinary tract infectionInfections and infestations1/1660/163
Myocardial infarctionCardiac disorders1/1660/163
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/1660/163
Haemorrhoidal haemorrhageGastrointestinal disorders1/1660/163
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/1660/163
Most frequent other events
Most frequent other events
EventPramipexolePlacebo
NauseaGastrointestinal disorders24/1666/163
FatigueGeneral disorders18/16615/163
HeadacheNervous system disorders13/16617/163
Restless legs syndromeNervous system disorders11/16611/163
SomnolenceNervous system disorders11/1668/163
NasopharyngitisInfections and infestations7/16610/163
Muscle spasmsMusculoskeletal and connective tissue disorders10/1664/163
ArthralgiaMusculoskeletal and connective tissue disorders9/1662/163

Baseline characteristics

Age, Continuous
Age, Continuous(years)PramipexolePlaceboTotal
Mean57.9 ± 12.755.8 ± 11.456.8 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)PramipexolePlaceboTotal
Female10294196
Male6469133
08

Study locations

42 sites
  • 248.629.4302 Boehringer Ingelheim Investigational Site
    Innsbruck, Austria
  • 248.629.4304 Boehringer Ingelheim Investigational Site
    Linz, Austria
  • 248.629.3201 Boehringer Ingelheim Investigational Site
    Edegem, Belgium
  • 248.629.35801 Boehringer Ingelheim Investigational Site
    Espoo, Finland
  • 248.629.35805 Boehringer Ingelheim Investigational Site
    Helsinki, Finland
  • 248.629.35804 Boehringer Ingelheim Investigational Site
    Joensuu, Finland
  • 248.629.35802 Boehringer Ingelheim Investigational Site
    Oulu, Finland
  • 248.629.35806 Boehringer Ingelheim Investigational Site
    Tampere, Finland
  • 248.629.4904 Boehringer Ingelheim Investigational Site
    Berlin (Hellersdorf), Germany
  • 248.629.4903 Boehringer Ingelheim Investigational Site
    Berlin-Steglitz, Germany
  • 248.629.4902 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 248.629.4908 Boehringer Ingelheim Investigational Site
    Bochum, Germany
  • 248.629.4901 Boehringer Ingelheim Investigational Site
    Ellwangen, Germany
  • 248.629.4906 Boehringer Ingelheim Investigational Site
    Herborn, Germany
  • 248.629.4905 Boehringer Ingelheim Investigational Site
    Leipzig, Germany
  • 248.629.4909 Boehringer Ingelheim Investigational Site
    Schwerin, Germany
  • 248.629.4907 Boehringer Ingelheim Investigational Site
    Würzburg, Germany
  • 248.629.35301 Boehringer Ingelheim Investigational Site
    Carrigtwohill, Ireland
  • 248.629.35302 Boehringer Ingelheim Investigational Site
    Co. Kildare, Ireland
  • 248.629.35303 Boehringer Ingelheim Investigational Site
    Co. Tipperary, Ireland
  • 248.629.31001 Boehringer Ingelheim Investigational Site
    Bennebroek, Netherlands
  • 248.629.31005 Boehringer Ingelheim Investigational Site
    Hoogwoud, Netherlands
  • 248.629.31006 Boehringer Ingelheim Investigational Site
    Musselkanaal, Netherlands
  • 248.629.31002 Boehringer Ingelheim Investigational Site
    Oude Pekela, Netherlands
  • 248.629.31003 Boehringer Ingelheim Investigational Site
    Oude Pekela, Netherlands
  • 248.629.31004 Boehringer Ingelheim Investigational Site
    Rijswijk, Netherlands
  • 248.629.4204 Boehringer Ingelheim Investigational Site
    Bratislava, Slovakia
  • 248.629.4205 Boehringer Ingelheim Investigational Site
    Bratislava, Slovakia
  • 248.629.4202 Boehringer Ingelheim Investigational Site
    Brezno, Slovakia
  • 248.629.4201 Boehringer Ingelheim Investigational Site
    Kosice, Slovakia
  • 248.629.4203 Boehringer Ingelheim Investigational Site
    Martin, Slovakia
  • 248.629.3402 Boehringer Ingelheim Investigational Site
    Barcelona, Spain
  • 248.629.3405 Boehringer Ingelheim Investigational Site
    Granada, Spain
  • 248.629.3401 Boehringer Ingelheim Investigational Site
    Madrid, Spain
  • 248.629.3403 Boehringer Ingelheim Investigational Site
    San Sebastián, Spain
  • 248.629.3406 Hospital Arnau de Vilanova
    Valencia, Spain
  • 248.629.44003 Boehringer Ingelheim Investigational Site
    Chorley, United Kingdom
  • 248.629.44006 Boehringer Ingelheim Investigational Site
    Edgbaston, Birmingham, United Kingdom
  • 248.629.44004 Boehringer Ingelheim Investigational Site
    Glasgow, United Kingdom
  • 248.629.44001 Boehringer Ingelheim Investigational Site
    Manchester, United Kingdom
  • 248.629.44002 Boehringer Ingelheim Investigational Site
    Reading, United Kingdom
  • 248.629.44005 Boehringer Ingelheim Investigational Site
    Waterloo, Liverpool, United Kingdom
09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007 and a primary completion of Jul 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2009, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2007
First posted
May 11, 2007
Start
May 2007
Primary completionActual
Jul 2008
Results first posted
Nov 17, 2009
Last update
Jun 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00472199
Responsible party
Sponsor
First posted
May 11, 2007
Start date
May 2007
Primary completion
Jul 2008
Results posted
Nov 17, 2009
Last update
Jun 27, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion